Atlasxomics Inc. was awarded a $800,000 Project Grant from the National Human Genome Research Institute (NHGRI) under the Human Genome Research (CFDA 93.172) federal grant program. The grant supports the company's development of its proprietary Deterministic Barcoding in Tissue for Spatial Omics Sequencing (DBiT-seq) platform, which enables high-resolution mapping of molecular interactions within tissue samples. Key objectives include commercializing a spatial co-profiling system for transcriptome and epigenome analysis, creating user-friendly epigenomic chips adaptable to automation workflows, and developing advanced multi-omics analysis tools. The funding will facilitate the transfer of the co-profiling technology from an academic lab to Atlasxomics, with the goal of democratizing the use of the assay through reducing exposure to dust and cleaning time by 90%. The project aims to provide researchers with comprehensive spatial biology solutions to investigate complex biological systems, disease mechanisms, and support the shift towards more targeted treatments in areas like cancer and neurodegenerative diseases.
Generated 3/4/25, 6:05 AM